Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

被引：0
作者：
Samoilova, Iuliia G. [1 ]
Vaizova, Olga E. [1 ]
Stankova, Anastasia E. [1 ]
Matveeva, Mariia, V [1 ]
Podchinenova, Daria, V [1 ,4 ]
Kudlay, Dmitry A. [2 ,3 ]
Borozinets, Anastasiia A. [2 ]
Filippova, Tatyana A. [1 ]
Grishkevich, Ivan R. [1 ]
Partala, Anastasia, V [1 ]
Gerasimova, Diana A. [1 ]
机构：
[1] Siberia State Med Univ, Tomsk, Russia
[2] Sechenov First Moscow State Med Univ, Sechenov Moscow State Med Univ 1, Moscow, Russia
[3] Lomonosov Moscow State Univ, Moscow, Russia
[4] Inst Immunol, Natl Res Ctr, Moscow, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2024年 / 96卷 / 01期
关键词：
polymorphism; dipeptidyl peptidase-4 inhibitors; type 2 diabetes mellitus; GLP1R; DPP-4; KCNQ1; GLYCEMIC RESPONSE; EPIDEMIOLOGY; GENE;
D O I：
10.26442/00403660.2024.01.202553
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase -4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2, DPP -4, KCNQ1, KCNJ11, PNPLA3, PRKD1) are associated with the pharmacokinetic values and efficacy of dipeptidyl peptidase -4 inhibitors, which may be promising for personalizing the treatment of patients with type 2 diabetes mellitus.
引用
收藏
页码：63 / 67
页数：5
相关论文
共 31 条
  • [1] Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database
    Arai, Masanori
    Shirakawa, Jun
    Konishi, Hiromi
    Sagawa, Naoko
    Terauchi, Yasuo
    [J]. DIABETES CARE, 2018, 41 (09) : E130 - E132
  • [2] Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes
    Barata, Llilda
    Feitosa, Mary F.
    Bielak, Lawrence F.
    Halligan, Brian
    Baldridge, Abigail S.
    Guo, Xiuqing
    Yerges-Armstrong, Laura M.
    Smith, Albert, V
    Yao, Jie
    Palmer, Nicholette D.
    Van Wagner, Lisa B.
    Carr, J. Jeffrey
    Chen, Yii-Der, I
    Allison, Matthew
    Budoff, Matthew J.
    Handelman, Samuel K.
    Kardia, Sharon L. R.
    Mosley, Thomas H., Jr.
    Ryan, Kathleen
    Harris, Tamara B.
    Launer, Lenore J.
    Gudnason, Vilmundur
    Rotter, Jerome, I
    Fornage, Myriam
    Rasmussen-Torvik, Laura J.
    Borecki, Ingrid B.
    OConnell, Jeffrey R.
    Peyser, Patricia A.
    Speliotes, Elizabeth K.
    Province, Michael A.
    [J]. HEPATOLOGY COMMUNICATIONS, 2019, 3 (07) : 894 - 907
  • [3] Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®
    Carnovale, Carla
    Mazhar, Faizan
    Arzenton, Elena
    Moretti, Ugo
    Pozzi, Marco
    Mosini, Giulia
    Leoni, Olivia
    Scatigna, Marco
    Clementi, Emilio
    Radice, Sonia
    [J]. EXPERT OPINION ON DRUG SAFETY, 2019, 18 (11) : 1099 - 1108
  • [4] Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
    Cho, Y. K.
    Kang, Y. M.
    Lee, S. E.
    Lee, J.
    Park, J. -Y.
    Lee, W. J.
    Kim, Y. -J.
    Jung, C. H.
    [J]. DIABETES & METABOLISM, 2018, 44 (05) : 393 - 401
  • [5] Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
    Deacon, Carolyn F.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2020, 16 (11) : 642 - 653
  • [6] Feingold K.R., 2022, EFFECT INFLAMMATION
  • [7] Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes
    Ferreira, Mari Cassol
    Rossi da Silva, Maria Elizabeth
    Fukui, Rosa Tsuneshiro
    Arruda-Marques, Maria do Carmo
    Azhar, Salman
    dos Santos, Rosa Ferreira
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2019, 11 (1)
  • [8] KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors
    Gotthardova, Ivana
    Javorsky, Martin
    Klimcakova, Lucia
    Kvapil, Milan
    Schroner, Zbynek
    Kozarova, Miriam
    Malachovska, Zuzana
    Urgeova, Anna
    Zidzik, Jozef
    Tkac, Ivan
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 130 : 142 - 147
  • [9] GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
    Holst, Jens Juul
    Rosenkilde, Mette Marie
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (08) : E2710 - E2716
  • [10] A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins
    Javorsky, M.
    Gotthardova, I.
    Klimcakova, L.
    Kvapil, M.
    Zidzik, J.
    Schroner, Z.
    Doubravova, P.
    Gala, I.
    Dravecka, I.
    Tkac, I.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (09) : 941 - 944
1234